rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CTSO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      CytoSorbents Corp (CTSO) Q3 2026 Earnings Call Highlights: Cash Flow Breakeven, Margin ...

      CytoSorbents Corp (CTSO) hit operating cash flow breakeven and lifted product gross margin to 75% in Q3 2026, while outlining an early 2027 de novo submission for DrugSorb ATR.

      Nov 13Yahoo FinanceCTSO
      Cytosorbents earnings beat by $0.32, revenue fell short of estimates
      Nov 12Investing.comCTSO
      Earnings call transcript: CytoSorbents posts Q3 2026 cash-flow breakeven
      Nov 12Investing.comCTSO
      CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update

      CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.

      Nov 12Yahoo FinanceCTSO
      CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
      Oct 29MorningstarCTSO
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Telix Pharm Ltd (TLPPF) from The Globe and Mail including charting and trades.

      Oct 23The Globe and MailCTSO
      WBB Securities initiates CytoSorbents stock with Speculative Buy
      Oct 21Investing.comCTSO
      CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
      Sep 30MorningstarCTSO
      CytoSorbents Regains Nasdaq Compliance, Pursues Growth Initiatives

      Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCTSO
      CytoSorbents regains Nasdaq minimum bid price compliance
      Sep 23Investing.comCTSO
      CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
      Sep 23Yahoo FinanceCTSO
      Cytosorbents CEO Phillip Chan buys $22,644 in common stock
      Sep 16Investing.comCTSO
      Cytosorbents president & COO Vincent Capponi buys $12,536 in stock
      Sep 16Investing.comCTSO
      CytoSorbents at H.C. Wainwright conference: breakeven, drug hopes
      Sep 14Investing.comCTSO
      CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
      Sep 10MorningstarCTSO
      Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000
      Sep 9Investing.comCTSO
      CytoSorbents Announces One-for-Twenty Reverse Stock Split

      Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailCTSO
      CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

      Newsfile Press Release.

      Sep 4The Globe and MailCTSO
      CytoSorbents Announces Reverse Stock Split
      Sep 3MorningstarCTSO
      CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
      Sep 2Yahoo FinanceCTSO
      Cytosorbents Earnings Call Balances Progress and Risk

      Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailCTSO

      This is the newest page. Registered accounts read further back.